Cyclophosphamide treatment of interstitial pulmonary fibrosis in polymyositis/dermatomyositis.
Interstitial pulmonary fibrosis is a serious complication of inflammatory muscle disease associated with significant morbidity and mortality. We describe 3 consecutive cases complicating dermatomyositis (1 case, anti-Jo-1 antibody negative) and polymyositis (2 cases, anti-Jo-1 antibody positive) in which cyclophosphamide was added to prednisone therapy with favorable outcomes.
al-Janadi
M
M
Rheumatic Disease Unit, Ottawa General Hospital, University of Ottawa, ON, Canada.
Smith
C D
CD
Karsh
J
J
D000328:Adult; D000368:Aged; D003520:Cyclophosphamide / Q000627:therapeutic use*; D003882:Dermatomyositis / Q000150:complications* / Q000188:drug therapy; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D009220:Myositis / Q000150:complications* / Q000188:drug therapy; D011241:Prednisone / Q000627:therapeutic use; D011658:Pulmonary Fibrosis / Q000188:drug therapy* / Q000209:etiology
D003520:Cyclophosphamide; D011241:Prednisone